Anti-obesity effect of eucalyptus leaf extract containing oenothein B in healthy Japanese adults: a randomized, placebo-controlled, double-blind, parallel-group study

Authors

  • Keiichiro Sugimoto Research and Development Center, Nagaoka Co., Ltd., Ibaraki, Osaka 567-0005, Japan
  • Hiroyuki Fujisawa Tokyo Laboratory, Nagaoka Co., Ltd., Koto-ku, Tokyo 135-0015, Japan
  • Kazuya Nakagawa Research and Development Center, Nagaoka Co., Ltd., Ibaraki, Osaka 567-0005, Japan
  • Kazuo Yamamoto ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Naoko Suzuki ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Shin-ichiro Yamashita ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Yuta Takahashi ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Toshihiro Kakinuma ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Asami Baba ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Tsuyoshi Takara Medical Corporation Seishinkai, Takara Clinic, Shinagawa-ku, Tokyo 141-0022, Japan
  • Toshikazu Yamanouchi Diabetes Center, Kashiwa-Tanaka Hospital, Kashiwa, Chiba 277-0803, Japan

DOI:

https://doi.org/10.31989/ffhd.v12i5.927

Abstract

Background: Excessive ingestion of fructose can lead to obesity and related diseases. Eucalyptus leaf extract (ELE) contains oenothein B, which inhibits intestinal fructose absorption.

Objective: The antiobesity effects of ELE containing oenothein B were evaluated in healthy Japanese whose body mass index (BMI) was ≥ 23 and < 30 kg/m2.

Methods: A randomized, placebo-controlled, double-blind, parallel-group study was performed to evaluate the effect of ELE consumption, for 12 weeks at a 3.38 mg/day dose of oenothein B, on the abdominal visceral fat area (VFA) as the primary outcome. Results were compared to those of a placebo group.

Results: Of the 721 individuals who underwent screening, 198 were randomly allocated into two groups. A total of 95 subjects in the placebo group and 94 in the intervention group were established as the per-protocol set. VFA in the intervention group significantly decreased compared to that in the placebo group 12 weeks after initiating intervention. This reduction in VFA was considered to have clinical significance. Among the secondary outcomes, VFA, waist circumference, and muscle mass after 8 weeks, as well as body weight and BMI after 12 weeks, were significantly lower in the intervention group compared to the placebo group.

Conclusion: ELE containing oenothein B may be effective against obesity and related diseases by reducing VFA levels.

 

Keywords: human trial; Eucalyptus globulus; oenothein B; polyphenol; hydrolyzable tannin; ellagitannin; dietary fructose consumption; dietary survey; Calorie and Nutrition Diary; glucose transporter 5

Downloads

Published

2022-05-28

Issue

Vol. 12 No. 5 (2022): May 2022

Section

Research Articles

License

Authors retain the copyright of their articles and grant the Functional Food Center (FFC) and its journals the right of first publication under the terms of the Creative Commons Attribution 4.0 International License.

This license permits unrestricted use, distribution, and reproduction in any medium, including commercial use, provided the original author(s) and source are properly credited. Authors may post and share their published work freely, provided that the original publication in this journal is acknowledged.

By submitting to this journal, authors confirm that their manuscripts are original, not under consideration elsewhere, and that they hold the necessary rights to grant this license. The Functional Food Center encourages open scientific exchange and allows derivative and extended works, provided attribution to the original publication is maintained.